Endomyocardial Biopsy Market Share, Size, Trends, Industry Analysis Report, By Product (Forceps, Accessories); By Tip (Straight, Maxi-curved, Pre-curved); By End-use (Hospitals, Ambulatory Surgical Centers); By Region, And Segment Forecasts, 2023 - 2032
- Published Date:Jul-2023
- Pages: 114
- Format: PDF
- Report ID: PM3555
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global endomyocardial biopsy market was valued at USD 318.03 million in 2022 and is expected to grow at a CAGR of 6.6% during the forecast period. Market growth is influenced by multiple factors including the rise in cases of cardiovascular diseases (CVDs), advancements in diagnostic technologies, growing geriatric population, and increasing research and development activities. The increasing sedentary lifestyle of a significant portion of the population has resulted in a higher prevalence of various types of CVDs worldwide.
To Understand More About this Research: Request a Free Sample Report
Contributing factors include physical inactivity, smoking, high blood pressure, and obesity. As per the estimates of the CDC, around 60 percent of the adults in the U.S. alone do not engage in any kind of physical activity, while it is estimated that, nearly, 25 percent of adults don’t have active lifestyle. Moreover, it is also projected that around 30.8 Mn individuals in the U.S. smoke, and around 16 Mn are living with smoke related health issues.
The COVID-19 pandemic has caused a significant disruption in the healthcare industry, and the market has been negatively impacted as a result. Many healthcare resources were redirected towards managing the pandemic, which led to a reduction in non-essential procedures such as heart biopsies.
However, the pandemic has also highlighted the importance of early detection and treatment of underlying medical conditions, including cardiovascular diseases, which may increase the demand for endomyocardial biopsies in the future. The COVID-19 pandemic has made healthcare providers more aware of the risks associated with pre-existing heart conditions in COVID-19 patients. As a result, they may prioritize the diagnosis and treatment of these conditions, which could lead to an increase in demand for endomyocardial biopsies.
For Specific Research Requirements, Speak to Research Analyst
Industry Dynamics
Growth Drivers
With the increasing number of heart transplant procedures being performed worldwide, the demand for endomyocardial biopsy (EMB) procedures has also been on the rise. EMB is an essential tool for monitoring and assessing the health of the transplanted heart and detecting early signs of rejection. As a result, it is expected to continue to be used as a part of routine post-transplant care, thereby driving the demand for EMB procedures. As per the estimates of the United Network for Organ Sharing, in 2021, there were around 31,238 transplants were performed in the U.S., and this number is constantly increasing.
Report Segmentation
The market is primarily segmented based on product, tip, end-use, and region.
|
By Product |
By Tip |
By End-Use |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Forceps segment accounted for the largest market share in 2022
As EMB procedures require a high level of precision and accuracy, improved forceps with better grip and maneuverability is crucial. Forceps with enhanced features such as a better grip, increased durability, and improved maneuverability can help healthcare professionals perform EMB procedures more effectively and efficiently. As a result, the demand for forceps used in EMB procedures is expected to increase with the growing need for accurate diagnosis and treatment of heart conditions. Availability of a forceps in different sizes & shapes from different manufacturers like, Argon Medical., Cordis, among others is meeting the needs of different patients & procedures, thus driving the demand for forceps in the EMB procedures.
Accessories segment recorded steady growth over the study period. The development of new and improved accessories such as flexible needles and improved imaging tools has contributed to the growth of the segment. These advancements provide greater accuracy and precision in EMB procedures, which can improve patient outcomes and reduce the risk of complications. Additionally, the availability of a range of accessories to suit different patient needs and procedure types has also driven market growth.
Straight tip segment held the significant market revenue share in 2022
Straight tip segment held the maximum market share in terms of revenue in 2022. The straight tip is preferred due to its design, which enables precision and accuracy during the biopsy procedure. The use of a straight tip reduces the risk of tissue damage, ensuring that the collected tissue is suitable for an accurate diagnosis. This type of forceps is commonly used for the initial puncture and navigation through the heart, enabling the collection of a tissue sample. These factors are expected to continue driving the growth of the straight tip segment.
Pre-curved segment recorded steady growth over the study period. Pre-curved tips are particularly useful in challenging anatomies and in cases where the target area is difficult to reach. The pre-curved design allows for more precise navigation and access to the targeted tissue, resulting in more accurate diagnosis and treatment. These advantages of pre-curved tips are expected to drive their adoption in the coming years, leading to significant growth of the segment in the EMB market.
Ambulatory segment is anticipated to witness highest growth
Ambulatory surgical centers segment is anticipated to grow at a healthy CAGR during the forecast period. ASCs have become increasingly popular among patients seeking more affordable and convenient options for medical procedures. As EMB procedures can now be safely and effectively performed in an ASC setting, many patients opt for ASCs over hospital-based procedures. This has led to a significant increase in the demand for EMB procedures in ASCs, which is expected to continue during the forecast period.
Hospital segment led the industry market with substantial market share in 2022. Increasing number of heart transplants and the availability of advanced medical facilities, which enable hospitals to perform EMB procedures more effectively. Hospitals are also equipped with advanced diagnostic and imaging technologies that aid in the accurate diagnosis of heart conditions. Additionally, the rising number of hospitals globally is expected to boost the endomyocardial biopsy market growth, as it will increase the availability of healthcare services to more people.
North America region dominated the global market in 2022
The North America region dominated the global market with considerable market share in 2022. Region has several leading market players, such as Medtronic, Boston Scientific Corporation, & Biosense Webster, which are investing heavily in research and development activities to develop advanced EMB procedures. Additionally, the region has a high adoption rate of advanced healthcare technologies, such as minimally invasive procedures, which are driving the growth of the EMB market in the region. The presence of well-established healthcare infrastructure and high healthcare expenditure are some other factors contributing to the region’s growth.
Asia Pacific region is expected to be the fastest growing region with a healthy CAGR over the study period. Additionally, the rising prevalence of cardiovascular diseases, growing healthcare expenditure, and increasing investments by key market players in the region are also expected to drive market growth. The region also has a large population base and a growing geriatric population, which is more prone to heart diseases, further contributing to market growth.
Competitive Insight
Some of the major players operating in the global market include Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, Changzhou Lookmed, and Fehling Instruments.
Recent Developments
- In May 2022, Terumo Corp. signed partnership agreement with the Argon Medical for the advanced unmet medical needs, to support diagnosis and treatment of the patients.
Endomyocardial Biopsy Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 338.13 million |
|
Revenue forecast in 2032 |
USD 599.52 million |
|
CAGR |
6.6% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments covered |
By Product, By Tip, By End Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, Changzhou Lookmed, and Fehling Instruments. |
FAQ's
key companies in Endomyocardial Biopsy Market are Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, Changzhou Lookmed.
The global endomyocardial biopsy market expected to grow at a CAGR of 6.6% during the forecast period.
The Endomyocardial Biopsy Market report covering key are product, tip, end-use, and region.
key driving factors in Endomyocardial Biopsy Market are Untapped opportunities in developing economies.
The global endomyocardial biopsy market size is expected to reach USD 599.52 million by 2032.
